DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR
摘要
The present invention relates to an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for use in methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of said compound for at least two five-consecutive day cycles, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles.
申请公布号
CA2930359(A1)
申请公布日期
2015.06.11
申请号
CA20142930359
申请日期
2014.12.03
申请人
NOVARTIS AG
发明人
DI TOMASO, EMMANUELLE;GERMA, MARIE-CAROLINE;MASSACESI, CRISTIAN;FRITSCH, CHRISTINE;SCHNELL, CHRISTIAN RENE;TAVORATH, RANJANA